Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Govi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|May 4, 2010
Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trialSilvia Govi, Giuseppina P Dognini, Giada Licata, et al.
Haematologica|September 13, 2003
Questions and answers in the management of primary central nervous system and ocular lymphomasAndrés J M Ferreri, Stefania Dell'oro, Michele Reni, et al.
The Oncologist|July 2, 2013
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphomaMaurilio Ponzoni, Silvia Govi, Giada Licata, et al.
Clinical Breast Cancer|May 22, 2012
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancerHenri Roché, Elena De Benedictis, Ewa Cottura, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
The Oncologist|November 11, 2011
Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomasMaurilio Ponzoni, Andrés J M Ferreri, Silvia Mappa, et al.
Blood Advances|March 18, 2020
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serumAndrés J M Ferreri, Marianna Sassone, Elisabetta Miserocchi, et al.
British Journal of Haematology|August 29, 2012
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphomaAndrés J M Ferreri, Marta Bruno Ventre, Giovanni Donadoni, et al.
Blood|November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trialAndrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?Andrés J M Ferreri, Giuseppina P Dognini, Silvia Govi, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|May 4, 2010
Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trialSilvia Govi, Giuseppina P Dognini, Giada Licata, et al.
Haematologica|September 13, 2003
Questions and answers in the management of primary central nervous system and ocular lymphomasAndrés J M Ferreri, Stefania Dell'oro, Michele Reni, et al.
The Oncologist|July 2, 2013
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphomaMaurilio Ponzoni, Silvia Govi, Giada Licata, et al.
Clinical Breast Cancer|May 22, 2012
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancerHenri Roché, Elena De Benedictis, Ewa Cottura, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
The Oncologist|November 11, 2011
Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomasMaurilio Ponzoni, Andrés J M Ferreri, Silvia Mappa, et al.
Blood Advances|March 18, 2020
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serumAndrés J M Ferreri, Marianna Sassone, Elisabetta Miserocchi, et al.
British Journal of Haematology|August 29, 2012
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphomaAndrés J M Ferreri, Marta Bruno Ventre, Giovanni Donadoni, et al.
Blood|November 3, 2012
Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trialAndrés J M Ferreri, Silvia Govi, Markus Raderer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?Andrés J M Ferreri, Giuseppina P Dognini, Silvia Govi, et al.
Pageof 3